Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Completed Initiated Jul 2, 2019 (7 years ago)

Polycin (bacitracin zinc and polymyxin B sulfate)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Polycin (bacitracin zinc and polymyxin B sulfate) Ophthalmic Ointment USP, Net. Wt. 3.5 g (1/8 oz.), Rx only, Manufactured for Perrigo, Minneapolis, MN 55427, NDC 0574-4021-35

Affected NDC 0574-4021-35

Compare with the code on your package — it is the most precise check available.

Drug: Zinc Category: Eye Drops & Ophthalmic

Recalling firm
Altaire Pharmaceuticals, Inc.
NDC code
0574-4021-35
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0355-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Zinc recalls

See all
Class II · Moderate risk

Zicam

CGMP Deviations; FDA inspection of the contract manufacturer noted out of limit results for microbiological testing

Ongoing Microbial contamination Church & Dwight Co., Inc. D-0790-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0642-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0641-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0637-2026

Other recalls by Altaire Pharmaceuticals, Inc.

All 2019 recalls